By Patrick Wingrove

(Reuters) -Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday.

Lilly said it would invest $6.5 billion to build the plant in Houston, Texas, as part of its $27 billion, four-site U.S. build-out plan for the next five years.

The Houston facility will make the active pharmaceutical ingredients for orforglipron and for some of Lilly’s cancer, autoimmune and other advanced therapies, the company said.

Lilly Chief Executive David Ricks told Reuters the new plant would be a major hub for orforglipron production, although the drug will also be made at a site in Indiana.

“This site will make orforglipron primarily and some of the precu

See Full Page